|
1
|
Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure.
|
Blood
|
2003
|
1.29
|
|
2
|
The pleiotropic role of the fibrinogen gamma' chain in hemostasis.
|
Blood
|
2009
|
1.25
|
|
3
|
Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity.
|
Blood
|
2007
|
0.99
|
|
4
|
Substrates of Factor XIII-A: roles in thrombosis and wound healing.
|
Clin Sci (Lond)
|
2013
|
0.96
|
|
5
|
Fibrin clot structure in patients with end-stage renal disease.
|
Thromb Haemost
|
2007
|
0.95
|
|
6
|
α-α Cross-links increase fibrin fiber elasticity and stiffness.
|
Biophys J
|
2012
|
0.93
|
|
7
|
Complement C3 is a novel plasma clot component with anti-fibrinolytic properties.
|
Diab Vasc Dis Res
|
2012
|
0.90
|
|
8
|
Association of coagulation factor XIII-A with Golgi proteins within monocyte-macrophages: implications for subcellular trafficking and secretion.
|
Blood
|
2010
|
0.90
|
|
9
|
Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes.
|
Diabetes Care
|
2012
|
0.82
|
|
10
|
Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity.
|
Blood
|
2013
|
0.79
|
|
11
|
Factor XIII A-subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy, middle-aged men.
|
Br J Haematol
|
2002
|
0.78
|
|
12
|
Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation.
|
Br J Haematol
|
2012
|
0.75
|
|
13
|
BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
|
Thromb Haemost
|
2016
|
0.75
|
|
14
|
Role of proteomic technologies in understanding risk of arterial thrombosis.
|
Expert Rev Proteomics
|
2009
|
0.75
|